DNAPrint Genomics Stock

DNAPrint Genomics EV/EBIT

EV/EBIT (Enterprise Value to EBIT) of DNAPrint Genomics (DNAG) as of Jul 28, 2026.

EV/EBIT

-0.00

Last updated:

EV/EBIT (Enterprise Value to EBIT) of DNAPrint Genomics is 2026 -0.00 . EV/EBIT (Enterprise Value to EBIT) of DNAPrint Genomics was 2025 - . It decreases by % lower compared to the previous year.

The DNAPrint Genomics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2000
0.00 base
Jan 1, 2001
0.00 base
Jan 1, 2002
0.00 base
Jan 1, 2003
0.00 base
Jan 1, 2004
0.00 base
Jan 1, 2005
0.00 base
Jan 1, 2006
0.00 base
YEARPRICE-TO-EBIT
2006 -
2005 -
2004 -
2003 -
2002 -
2001 -
2000 -
Access this data via the Eulerpool API

DNAPrint Genomics Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides DNAPrint Genomics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates DNAPrint Genomics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots DNAPrint Genomics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if DNAPrint Genomics grows earnings faster than its peers.

DNAPrint Genomics Stock analysis

What does DNAPrint Genomics do? DNAPrint Genomics Inc. was an American company specializing in researching genetic differences and their impact on health, diagnostics, and forensic applications. Founded in Sarasota, Florida in 1997, originally named Genaissance Pharmaceuticals, the company focused on medical research. In 2005, it changed its name to DNAPrint Genomics and shifted its focus to genetic testing development. The company's business model included developing and marketing molecular tests that can reveal an individual's genetic background, providing access to new markets and customers. DNAPrint Genomics offered various product lines for disease diagnosis, including tests for identifying and diagnosing specific diseases like breast cancer, colon cancer, and Alzheimer's. They also provided diagnostics for personalized medicine, matching medication to individuals' genetic predispositions. However, the company gained attention primarily for its forensic applications. They developed a system called DNAWitness, allowing comparison of unknown DNA samples with DNA databases to create offender profiles. The system was used by law enforcement agencies in the U.S. to aid crime investigation and was also involved in international police collaborations. DNAPrint Genomics pursued patents and partnerships with other companies to expand access to new technologies and developments, aiming to position itself in the international market. In 2008, the company announced its discontinuation due to economic reasons, facing complications in selling its DNAWitness system and encountering difficulties in selling its diagnostic tests. Despite having promising products, the company was unable to stabilize its market position and become profitable. DNAPrint Genomics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DNAPrint Genomics stock

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) DNAPrint Genomics since 2006 – with annual values, charts, and detailed analysis.

Access this data via the Eulerpool API

Valuation — DNAPrint Genomics

All Key Metrics — DNAPrint Genomics